Legend Biotech’s LB2102 Yields 28.6% ORR, 78.6% DCR; Novartis T-Charge to Cut Vein-To-Vein Times
LEGN•Legend Biotech’s LB2102 CAR-T therapy showed a 28.6% ORR and 78.6% DCR at ≥2.0×10^6 cells/kg in 20 r/r ES-SCLC/LCNEC patients, compared with 35% ORR and 68% DCR for standard Imdelltra. Prolonged 8–10 week vein-to-vein times may hinder outcomes, prompting Novartis to pursue a faster T-Charge platform.
1. Trial Design and Patient Enrollment
Legend Biotech initiated a Phase I/II study of LB2102 in 20 relapsed or refractory ES-SCLC and LCNEC patients across seven dose levels, excluding those with prior Imdelltra exposure and expanding eligibility beyond standard bispecific trials.
2. Efficacy Results and Comparative Benchmarks
At dose levels ≥2.0×10^6 CAR-T cells/kg, LB2102 delivered a 28.6% overall response rate and 78.6% disease control rate with a median duration of response of 6.5 months, versus Imdelltra’s 35% ORR, 68% DCR and 6.9-month mDOR in its pivotal trial.
3. Manufacturing Timelines and T-Charge Platform
Initial vein-to-vein times averaged 8–10 weeks, during which patients received bridging chemotherapy and risked progression, driving Novartis to leverage its T-Charge process that can produce autologous CAR-T cells in two days and potentially deliver doses within two weeks.
4. Future Outlook and Competitive Landscape
Analyst consensus forecasts project LB2102 sales of $22 million by 2032, but emerging trispecific DLL3 T-cell engagers like alveltamig could redefine benchmarks as Novartis gears up a separate ES-SCLC development program.
